Janssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis

Press/Media: Press / Media

PeriodApr 23 2015 → Apr 24 2015

Media coverage

38

Media coverage

  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outletNational AIDS Treatment Advocacy Project
    CountryUnited States
    Date4/24/15
    PersonsEric J Lawitz
  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outletSys-Con India
    CountryIndia
    Date4/23/15
    PersonsEric J Lawitz
  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outletTickerTech.com
    CountryUnited States
    Date4/23/15
    PersonsEric J Lawitz
  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outletSys-Con Australia
    CountryAustralia
    Date4/23/15
    PersonsEric J Lawitz
  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outletPipelineReview
    CountrySpain
    Date4/23/15
    PersonsEric J Lawitz
  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir..
    Media name/outletADVFN India
    CountryIndia
    Date4/23/15
    PersonsEric J Lawitz
  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outletPharmacy Choice
    CountryUnited States
    Date4/23/15
    PersonsEric J Lawitz
  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outletMichigan Live
    CountryUnited States
    Date4/23/15
    PersonsEric J Lawitz
  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outletWBOY
    CountryUnited States
    Date4/23/15
    PersonsEric J Lawitz
  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outletWJTV.com
    CountryUnited States
    Date4/23/15
    PersonsEric J Lawitz
  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outletChannel 8 Eyewitness News
    CountryUnited States
    Date4/23/15
    PersonsEric J Lawitz
  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outletNebraska TV
    CountryUnited States
    Date4/23/15
    PersonsEric J Lawitz
  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outletWSPA
    CountryUnited States
    Date4/23/15
    PersonsEric J Lawitz
  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outletWRBL-TV
    CountryGeorgia
    Date4/23/15
    PersonsEric J Lawitz
  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outletWTRF
    CountryUnited States
    Date4/23/15
    PersonsEric J Lawitz
  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outletKSTC-TV
    CountryUnited States
    Date4/23/15
    PersonsEric J Lawitz
  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outletWKRG
    CountryUnited States
    Date4/23/15
    PersonsEric J Lawitz
  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outletWNCT
    CountryUnited States
    Date4/23/15
    PersonsEric J Lawitz
  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outletABC6.com
    CountryUnited States
    Date4/23/15
    PersonsEric J Lawitz
  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outlet3 WRCB-TV
    CountryUnited States
    Date4/23/15
    PersonsEric J Lawitz
  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outletWCBD
    CountryUnited States
    Date4/23/15
    PersonsEric J Lawitz
  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outletWave 3
    CountryUnited States
    Date4/23/15
    PersonsEric J Lawitz
  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outletWAND TV
    CountryUnited States
    Date4/23/15
    PersonsEric J Lawitz
  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outletNBC WAGT 26
    CountryGeorgia
    Date4/23/15
    PersonsEric J Lawitz
  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outletKFVE
    CountryUnited States
    Date4/23/15
    PersonsEric J Lawitz
  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outletWSAV
    CountryGeorgia
    Date4/23/15
    PersonsEric J Lawitz
  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outletKMPH Fox 26
    CountryUnited States
    Date4/23/15
    PersonsEric J Lawitz
  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outletFox41.com
    CountryUnited States
    Date4/23/15
    PersonsEric J Lawitz
  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outletKXNet.com
    CountryUnited States
    Date4/23/15
    PersonsEric J Lawitz
  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outletKuam News 8
    CountryGuam
    Date4/23/15
    PersonsEric J Lawitz
  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outlet35 WSEE
    CountryUnited States
    Date4/23/15
    PersonsEric J Lawitz
  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outletKPLC TV
    CountryUnited States
    Date4/23/15
    PersonsEric J Lawitz
  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outletAZ-TV7
    CountryUnited States
    Date4/23/15
    PersonsEric J Lawitz
  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outletWLTZ 38
    CountryGeorgia
    Date4/23/15
    PersonsEric J Lawitz
  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outletGTN News
    CountryUnited States
    Date4/23/15
    PersonsEric J Lawitz
  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outletWXTX Fox 54
    CountryGeorgia
    Date4/23/15
    PersonsEric J Lawitz
  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outletKUSI.com
    CountryUnited States
    Date4/23/15
    PersonsEric J Lawitz
  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outletBioPortfolio
    CountryUnited Kingdom
    Date4/23/15
    PersonsEric J Lawitz